PIGW
protein-codingphosphatidylinositol glycan anchor biosynthesis class W, the group of Phosphatidylinositol glycan anchor biosynthesis
Gene summary
The protein encoded by this gene is an inositol acyltransferase that acylates the inositol ring of phosphatidylinositol. This occurs in the endoplasmic reticulum and is a step in the biosynthesis of glycosylphosphatidylinositol (GPI), which anchors many cell surface proteins to the membrane. Defects in this gene are a cause of the age-dependent epileptic encephalopathy West syndrome as well as a syndrome exhibiting hyperphosphatasia and cognitive disability (HPMRS5). [provided by RefSeq, Jul 2017]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~4.3 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0012465
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0015286
Submitter: ClinGen
*PIGW* was first reported in relation to autosomal recessive congenital disorder of glycosylation (also known as glycosylphosphatidylinositol (GPI) biosynthesis defect 11) in 2014 (Chiyonobu T et al., PMID:24367057). This rare congenital glycosylation disorder is characterized by hypotonia, severe developmental delay, intellectual disability, seizures, increased serum alkaline phosphatase, and dysmorphic facial features. Defects in this gene have been identified as a cause of age-dependent epileptic spasms (West syndrome) as well as a syndrome exhibiting hyperphosphatasia and cognitive disability (HPMRS5) [provided by RefSeq, Jul 2017]. It is caused by mutations in the *PIGW* gene, which functions in the third step of GPI biosynthesis by acylating the inositol ring of phosphatidylinositol and encodes a 504–amino acid inositol acyltransferase (Murakami et al., 2003, PubMed:14517336). Eight variants (missense) that have been reported in 6 probands in 6 publications (Chiyonobu T et al., 2014, PMID:24367057; Hogrebe M et al., 2016, PMID:27626616; Meier N et al., 2019, PMID:30679815; Fu L et al., 2019, PMID:30813920; Peron A et al., 2020, PMID:32198969; and Foskett GK et al., 2018, PMID: ), are included in this curation. This gene-disease relationship is also supported by a rescue in cell culture model that mimics a specific inherited GPI deficiency and assesses the effectiveness of various synthetic compounds in reestablishing normal GPI biosynthesis. (Guerrero PA et al., 2021, PMID:34618440). In summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Congenital Disorder of Glycosylation GCEP on the meeting date February 6, 2025 (SOP Version 11).
Inheritance Pattern: AR
Disease ID:MONDO:0014457
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0014457
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0014457
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0016596
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0014457
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Gastrointestinal; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PIGW variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001346754.2. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 101 | 2 | 103 | |||
| missense | 5 | 178 | 10 | 1 | 194 | |
| nonsense | 2 | 9 | 11 | |||
| start loss | 1 | 1 | ||||
| frameshift | 2 | 20 | 22 | |||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 5 | 5 | 207 | 111 | 3 | 331 |
Highest pathogenic variant AF is 0.00019452818
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001333683.1 | 1 | MANE Select | |
| Ensembl | ENSP00000482202.1 | 1 | MANE Select | |
| RefSeq | NP_001333684.1 | 1 | Standard | |
| RefSeq | NP_848612.2 | 1 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Glycosylphosphatidylinositol (GPI)-anchor biosynthesis - Homo sapiens (human)
- Synthesis of glycosylphosphatidylinositol (GPI)
- Post-translational modification: synthesis of GPI-anchored proteins
- Post-translational protein modification
- Metabolism of proteins
Biological Process
- GPI anchor metabolic process
- GPI anchor biosynthetic process
- preassembly of GPI anchor in ER membrane
- protein localization to plasma membrane
Molecular Function
- O-acyltransferase activity
- glucosaminyl-phosphotidylinositol O-acyltransferase activity
Cellular Component
- endoplasmic reticulum membrane
- integral component of membrane
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Required for the transport of GPI-anchored proteins to the plasma membrane (PubMed:24367057). Probable acetyltransferase, which acetylates the inositol ring of phosphatidylinositol during biosynthesis of GPI-anchor. Acetylation during GPI-anchor biosynthesis is not essential for the subsequent mannosylation and is usually removed soon after the attachment of GPIs to proteins (By similarity). {ECO:0000250|UniProtKB:Q7TSN4, ECO:0000269|PubMed:24367057}.;
- Disease
- DISEASE: Glycosylphosphatidylinositol biosynthesis defect 11 (GPIBD11) [MIM:616025]: An autosomal recessive neurologic disorder characterized by developmental delay, mental retardation, tonic seizures associated with hypsarrhythmia, dysmorphic facial features, and elevated serum alkaline phosphatase. {ECO:0000269|PubMed:24367057}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.0819
Intolerance Scores
- LoFtool
- 0.297
- RVIS EVS
- -0.03
- RVIS percentile EVS
- 51.92
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.442
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |